Source of material
Title compound was synthesized by condensation of 4-(l,2,4-triazol-l-yl-methyl) benzonitrile with ethyl 4-fluorophenylacetate in DMF using potassium /-butoxide as a base. The intermediate ketone was reduced by sodium borohydride to give 4-[3-(4-fluorophenyl)-2-hydroxy-l-(l,2,4-triazol-l-yl)-propyl]-benzonitrile. The two diastereomeric racemates were separated by crystallization. Title compound is the less soluble enantiomer pair. Crystal suitable for X-ray work were obtained from water-ethanol mixture and mounted on the glass fiber using the oil drop method [ 1 ] . The mass spectrum was recorded on Micromass LCT instrument by time of flight (TOF) analysator using electrospray ionisation technique. The main peak of the spectrum appears at 323 (MIT corded on a Bruker DPX 400 instrument in DMSO-dk using tetramethylsilane as an internal reference. NMR data are included in the deposited CIF-file.
Experimental details
The intensity data were corrected for Lorentz and polarization effects and for absorption and extinction. All non H atoms were refined anisotropically. H atoms were localized from difference Fourier maps and refined isotropically.
Discussion
Aromatase is a cytochrome P450 enzyme which catalyses the conversion of androgens to estrogens. Aromatase inhibitors are potentially useful in the endocrine therapy of estrogen dependent diseases, such as breast cancer. The title compound, Finrozole, is a new competitive, highly potent and selective nonsteroidal aromatase inhibitor [2] , The compound was found to crystallize as RS and SR racemate. 
